Megaloblastic maturation is the morphologic result of any biochemical defect that causes a slowing of DNA synthesis. The hallmark of this megaloblastosis is nuclear-cytoplasmic dissociation; the ...

A compound effective in killing chemotherapy-resistant glioblastoma-initiating cells (GICs) has been identified, raising hopes of producing drugs capable of eradicating refractory tumors with low ...

Findings from the phase 3 ASCLEPIOS I and II studies showed that treatment with ofatumumab (Novartis), a CD20-directed cytolytic monoclonal antibody, resulted in a highly significant and clinically ...

For many years, RA was treated primarily with nonsteroidal anti-inflammatory drugs (NSAIDs). While NSAIDS, including the newer generation cyclo-oxygenase (COX-2) inhibitors, decrease inflammation and ...

One of French drugmaker Sanofi’s top-selling products could face some significant competition after the presentations of two Phase III studies at a multiple sclerosis conference of drugs shown to have ...

The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Aubagio (teriflunomide; Genzyme) that includes revisions to the Contraindications, Warnings and ...

The usual Aubagio (teriflunomide) dosage is 7 or 14 milligrams (mg) taken once per day. Your dosage might vary based on factors like how severe your condition is and other medications you take.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolves rapidly under the pressure of host immunity, as evidenced by waves of emerging variants despite effective vaccinations, ...